Development · 4 Sep 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Cohance Lifesciences plans to invest a combined $18 million in NJ Bio and Aruka Bio to deepen its push into antibody-drug conjugates.
Cohance Lifesciences will invest $18 million in NJ Bio and Aruka Bio to strengthen its antibody-drug conjugate strategy, increasing its NJ Bio ownership to 67.3% and taking a 65% stake in Aruka Bio.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.